The primary outcome was non-inferiority of IDeg @TW compared with IGlar OD , as assessed by change in HbA ( @c ) from baseline to @ weeks ( non-inferiority limit of @ % ) by ANOVA in an intent-to-treat analysis ( full analysis set ) .